1. Home
  2. VTEX vs LXRX Comparison

VTEX vs LXRX Comparison

Compare VTEX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

HOLD

Current Price

$3.94

Market Cap

561.5M

Sector

Technology

ML Signal

HOLD

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.70

Market Cap

547.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTEX
LXRX
Founded
1999
1995
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
561.5M
547.4M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
VTEX
LXRX
Price
$3.94
$1.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$6.16
$4.63
AVG Volume (30 Days)
1.0M
2.3M
Earning Date
01-01-0001
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.78
EPS
N/A
N/A
Revenue
N/A
$49,803,000.00
Revenue This Year
$12.64
N/A
Revenue Next Year
$10.57
$22.16
P/E Ratio
$43.33
N/A
Revenue Growth
N/A
60.24
52 Week Low
$2.84
$0.32
52 Week High
$6.82
$1.83

Technical Indicators

Market Signals
Indicator
VTEX
LXRX
Relative Strength Index (RSI) 74.10 66.31
Support Level $3.92 $1.08
Resistance Level $4.23 $1.83
Average True Range (ATR) 0.16 0.12
MACD 0.11 0.02
Stochastic Oscillator 97.70 84.83

Price Performance

Historical Comparison
VTEX
LXRX

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: